Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 262

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 262
---
 |       698,558 |     |   1.9 |   |     |     1,000,000 |     |   2.8 |   |
| Total                                     |     |     35,205,673 |     | 100.0 | % |     |    35,259,086 |     | 100.0 | % |     |    35,312,500 |     | 100.0 | % |

____________ Notes:- (1)Assumes that no Public Shares are redeemed. (2)Assumes that 260,028 Public Shares are redeemed. (3)Assumes that all 520,056 Public Shares are redeemed. (4)Corresponds to 3,342,188 Company Shares to be issued to Sponsor. (5)Corresponds to 970,312 Company Shares to be issued to the Initial Sponsor. (6)Prior to Closing, the Parent expects to redeem a portion of the Parent shares held by Theo, and Theo expects to subsequently distribute a total of 1,500,000 Company Shares to between 300 and 424shareholders of Bioceres S.A. and Bioceres Group, which is consistent with Bioceres Group PLC’s policy to distribute shares of its investees to its limited partners, so that they hold shares directly, and not through any investment vehicle. (7)Company Shares issued to Theo pursuant to the Backstop Agreement assuming that it satisfies its obligations thereunder pursuant to the subscription of up to 1,000,000 Company Shares at an issue price of $10.00 per Company Share (par value of $0.0001) and making a cash contribution in an amount of up to $10,000,000 that exceeds the aggregate amount of cash on deposit in the Trust Account (including any interest earned on the funds held in the Trust Account) remaining after payment in full of the SPAC Shareholder Redemption Amount. See “ Questions and Answers about the Business Combination and the Special Meeting — Q. What equity stake will our current shareholders and shareholders of the Target hold in OmnigenicsAI immediately after consummation of the Business Combination” and “ Certain Agreements Related to the Business Combination — Backstop Agreement.” On September8, 2023, APx issued the Working Capital Promissory Note in the principal amount of $500,000 to Templar Sponsor. The Templar Note does not bear interest and the principal balance will be payable on the Maturity Date